Patient Reported Satisfaction With Contoura LASIK Utilizing the Phorcides Analytic Software
1 other identifier
observational
50
1 country
1
Brief Summary
The objective is to determine the percentage of subjects satisfied (Completely Satisfied or Very Satisfied) with vision after Phorcides Planned Contoura LASIK.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 28, 2023
CompletedFirst Posted
Study publicly available on registry
May 8, 2023
CompletedStudy Start
First participant enrolled
May 19, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 15, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2024
CompletedResults Posted
Study results publicly available
July 17, 2025
CompletedJuly 17, 2025
July 1, 2025
1.2 years
April 28, 2023
June 30, 2025
July 16, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Subject Satisfaction
Percentage of subjects satisfied with vision after Phorcides Planned Contoura LASIK (answering Completely Satisfied or Very Satisfied on PROWL Questionnaire Question #1.
3 Months Postoperative
Secondary Outcomes (1)
Number of Eyes With Post-op Spherical Equivalent Within +/- 0.50 D
3 Months Postoperative
Other Outcomes (2)
PROWL Questionnaire
3 Months Postoperative
OSDI Score
3 Months Postoperative
Study Arms (1)
Contoura LASIK
Subjects receiving Phorcides Planned Contoura LASIK.
Interventions
Eligibility Criteria
Subjects 21 to 39 years of who are appropriate candidates for laser refractive surgery.
You may not qualify if:
- Subjects with history of previous ocular surgery.
- Subjects with topographic evidence of keratoconus, or ectasia.
- Subjects with autoimmune diseases.
- Subjects who are pregnant or nursing.
- Systemic disease likely to affect wound healing, such as diabetes and severe atopy.
- Any ocular disease (including un-controlled dry eye) which in the investigator's opinion would affect the outcome of refractive surgery.
- The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.
- Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mann Eye Institutelead
- Sengicollaborator
Study Sites (1)
Mann Eye Institute
Houston, Texas, 76134-2099, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Phillip Brunson
- Organization
- Mann Eye Institute
Study Officials
- PRINCIPAL INVESTIGATOR
Phillip Brunson, OD
Mann Eye Institute
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 28, 2023
First Posted
May 8, 2023
Study Start
May 19, 2023
Primary Completion
August 15, 2024
Study Completion
August 15, 2024
Last Updated
July 17, 2025
Results First Posted
July 17, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share